Systemic Sclerosis

You have full text access to this OnlineOpen article

Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis

  1. Carmine Cardillo*,
  2. Francesca Schinzari,
  3. Domenico Melina,
  4. Nadia Mores,
  5. Silvia Bosello,
  6. Giusy Peluso,
  7. Angelo Zoli,
  8. Gianfranco Ferraccioli

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24502

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 6, pages 1840–1844, June 2009

Additional Information

How to Cite

Cardillo, C., Schinzari, F., Melina, D., Mores, N., Bosello, S., Peluso, G., Zoli, A. and Ferraccioli, G. (2009), Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. Arthritis & Rheumatism, 60: 1840–1844. doi: 10.1002/art.24502

Author Information

  1. Università Cattolica del Sacro Cuore, and Association Columbus, Rome, Italy

*Istituto di Patologia Speciale Medica e Semeiotica Medica, Università Cattolica del Sacro Cuore, Largo Gemelli 8, 00168 Rome, Italy

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 12 FEB 2009
  4. Manuscript Received: 8 SEP 2008

Funded by

  • Fondi d'Ateneo grant from the Università Cattolica del Sacro Cuore

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (71K)

REFERENCES

  • 1
    Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 2008; 34: 57–71.
  • 2
    Luscher TF, Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995; 118 Suppl: S81–90.
  • 3
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al, and the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985–93.
    Direct Link:
  • 4
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.
  • 5
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 6
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5.
  • 7
    Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002; 105: 452–6.
  • 8
    Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007; 56: 1985–93.
    Direct Link:
  • 9
    Verhaar MC, Strachan F, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, et al. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752–6.
  • 10
    Ruschitzka F, Quaschning T, Noll G, deGottardi A, Rossier MF, Enseleit F, et al. Endothelin 1 type A receptor antagonism prevents vascular dysfunction and hypertension induced by 11β-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 2001; 103: 3129–35.
  • 11
    Berger R, Stanek B, Hulsmann M, Frey B, Heher S, Pacher R, et al. Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure. Circulation 2001; 103: 981–6.
  • 12
    Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 1995; 26: 854–7.
  • 13
    Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222–9.
  • 14
    Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum 2007; 56: 4189–94.
    Direct Link:
  • 15
    Wancheeswaran R, Magoulas T, Efrat G, Wheele-Jons C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838–44.
View Full Article (HTML) Get PDF (71K)